Form 8-K - Current report:
SEC Accession No. 0001558370-21-011566
Filing Date
2021-08-13
Accepted
2021-08-13 07:05:22
Documents
15
Period of Report
2021-08-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20210812x8k.htm   iXBRL 8-K 47992
2 EX-10.1 plx-20210812xex10d1.htm EX-10.1 137383
3 EX-99.1 plx-20210812xex99d1.htm EX-99.1 20235
4 GRAPHIC plx-20210812xex99d1001.jpg GRAPHIC 11384
  Complete submission text file 0001558370-21-011566.txt   377752

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20210812.xsd EX-101.SCH 3195
6 EX-101.LAB plx-20210812_lab.xml EX-101.LAB 16162
7 EX-101.PRE plx-20210812_pre.xml EX-101.PRE 10907
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20210812x8k_htm.xml XML 4870
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 211169693
SIC: 2836 Biological Products, (No Diagnostic Substances)